[1] International Agency for Research on Cancer, World Health Organization. Live Source: Globocan 2020[EB/OL].https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf.
[2] 中国临床肿瘤学会指南工作委员会. 原发性肝癌诊疗指南2020. 人民卫生出版社. 2020.
[3] Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer, 2019 ,18:155.
[4] Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers, 2020, 6:38.
[5] McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol, 2019, 37:457-495.
[6] Wang J, Huang H, Liu Y, et al. HBV Genome and Life Cycle. Adv Exp Med Biol, 2020, 1179:17-37.
[7] Kubes P, Jenne C. Immune responses in the liver. Annu Rev Immunol, 2018, 36:247-277.
[8] Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med, 2020, 382:1894-1905.
[9] Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2021, 1-19.
[10] Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med, 2018, 378:113-125.
[11] André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med, 2020, 383:2207-2218.
[12] Pfister D, Nú?ez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 2021, 592:450-456.
[13] Yau T, Park JW, Finn RS, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol, 2019, 30:v874–v875.
[14] Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase iii trial. J Clin Oncol, 2020, 38: 193-202.
[15] Kowanetz M, Zou W, Gettinger SN, et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proc Natl Acad Sci U S A, 2018, 115:E10119-E10126.
[16] Patel SP, Kurzrock R. PD-L1 Expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther, 2015, 14: 847-856.
[17] Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature, 2016, 531:253-257.
[18] Ma C, Zhang Q, Greten TF. Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes. FEBS J, 2018, 285:752-762.
[19] Harrison SA, Rinella ME, Abdelmalek MF, et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2018, 391:1174-1185.
[20] Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med, 2021, 384:1113-1124.
[21] Wang WJ, Xiao P, Xu HQ, et al. Growing burden of alcoholic liver disease in China: A review. World J Gastroenterol, 2019, 25:1445-1456.
[22] enehan AG, Tyson M, Egger M, Heller RF, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet, 2008, 371:569-578.
[23] Anand P, Kunnumakkara AB, Sundaram C, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res, 2008, 25:2097-2116.
[24] Zhou J, Zhou F, Chu X, et al. Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases. Transl Lung Cancer Res, 2020, 9:316-324.
[25] McQuade JL, Daniel CR, Hess KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol, 2018, 19:310-322.
[26] Cortellini A, Bersanelli M, Buti S, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer, 2019, 7:57.
[27] Cucchetti A, Trevisani F, Pecorelli A, et al. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. J Hepatol, 2014, 61:333-341.
[28] Park SM, Yun YH, Kim YA, et al. Prediagnosis Body Mass Index and Risk of Secondary Primary Cancer in Male Cancer Survivors: A Large Cohort Study. J Clin Oncol, 2016, 34:4116-4124.
[29] Wang M, Wang Y, Feng X, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: experience of the Chinese national cancer center. Int J Infect Dis, 2017, 65:15-21.
[30] Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLDin China from 2008 to 2018: a systematic review and meta-analysis. Hepatology, 2019, 70:1119-1133. |
